NCT00672581View on ClinicalTrials.gov

Pharmacokinetics, Safety & Tolerability of ZD4054 (Zibotentan) in Subjects With Normal, Mild, Moderate and Severe Hepatic Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

April 30, 2008

Study Completion Date

March 31, 2009

Conditions

Hepatic Impairment

Interventions

DRUG

ZD4054

10mg, Oral tablet, single dose

Trial Locations (1)

Unknown

Research Site, Prague

Sponsors

Lead Sponsor

Collaborators (1)

PRA Health Sciences

All Listed Sponsors

collaborator

PRA Health Sciences

INDUSTRY

lead

AstraZeneca

INDUSTRY